Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,190 INR | +0.85% |
|
+0.28% | +8.58% |
26/06 | Indian Equities Close Higher Midweek, Aided by Banking, Media and Oil & Gas Stocks | MT |
17/06 | Fortis, Apollo, Medanta, and Max Lead the Charge in Bidding War for Jaypee Healthcare | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 57% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 94.59 and 59.72 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.82 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.58% | 1.06TCr | - | ||
-33.75% | 1.37TCr | B+ | ||
+4.15% | 1.17TCr | B+ | ||
-2.70% | 1.15TCr | B | ||
+28.69% | 851.77Cr | B | ||
-10.32% | 708.53Cr | A- | ||
+7.69% | 681.31Cr | B- | ||
+8.41% | 648.26Cr | D | ||
0.00% | 488.94Cr | - | - | |
+14.10% | 434.76Cr | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- APOLLOHOSP Stock
- APOLLOHOSP Stock
- Ratings Apollo Hospitals Enterprise Limited